15-12G - Renovacor, Inc. (0001799850) (Filer)

EFFECT - Renovacor, Inc. (0001799850) (Filer)

EFFECT - Renovacor, Inc. (0001799850) (Filer)

S-8 POS - Renovacor, Inc. (0001799850) (Filer)

S-8 POS - Renovacor, Inc. (0001799850) (Filer)

POS AM - Renovacor, Inc. (0001799850) (Filer)

POS AM - Renovacor, Inc. (0001799850) (Filer)

8-K - Renovacor, Inc. (0001799850) (Filer)

25-NSE - Renovacor, Inc. (0001799850) (Subject)

424B3 - Renovacor, Inc. (0001799850) (Filer)

Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t

Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di

Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for multiple genetic segments of arrhythmogenic cardiomyopathy Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program,

REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the first quarter of 2022 and provided a corporate update. "Our first quarter progress was highlighted by REN-001's continued advancement towards the clinic and by the addition of industry veteran Fred Drisc

Mr. Driscoll has over 25 years of biotech executive experience and most recently served as the CFO of Flexion Therapeutics through its sale to Pacira BioSciences for up to $1 billion Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced the appointment of Fred Driscoll as Chief Financial Officer (CFO). "Fred has a wealth of experience guiding financial strategy for publicly-traded biotech companies and we are thrilled to welcome him to Renovacor," said Magdalene Cook, M.D., Chief Executive Officer

Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew Killeen, Ph.D., as CSO and Elizabeth White, Ph.D., as CBO and SVP of Operations Reported topline preclinical data demonstrating successful cardiac transduction with REN-001 delivered via local infusion at a low vector dose in a pilot pig study Significant progress made across key ongoing REN-001 IND-enabling studies IND submission for REN-001 is expected in the second half of 2022 with the initiation of a Phase I/I

Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that Magdalene Cook, M.D., Chief Executive Officer, will present a corporate overview at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET. A webcast of the presentation will be available by visiting the Investors and Media section of Renovacor's website under "Events and Presentations." A replay of the webcast will be available on the Renovacor website for 30 days following the conference. About Renovacor

Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN). The company will provide sponsorship for initiatives to raise awareness of cardiomyopathies and to educate the patient and provider communities about the importance of genetic testing for patients and families living with DCM. "We are proud to be partnering with three great organ

Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced that Magdalene Cook, M.D., President and Chief Executive Officer of Renovacor, will participate in a panel presentation at the 11th Annual LifeSci Partners Corporate Access Event. Details on the panel are shown below: Title: Gene Therapy: Reaching its Full Potential Date: Thursday, January 6, 2022 Time: 11:00 a.m. ET Webcast Link: https://wsw.com/webcast/lifesci3/panel8/2389200 A replay of the panel presentation will be available by visiting the Investors and